Src and its associated focal adhesion kinase provide resistance of mesenchymal variants in non-small cell lung cancer to chemotherapeutic drugs, and the Src inhibitor dasatinib renders these tumours susceptible to anti-cancer agents such as erlotinib42. Here, SRC is linked to non-small cell lung carcinoma.